Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I-a)

wherein the compound of formula (I-a) is a polymorphic form selected from the group consisting of:

Form B characterized by X-ray powder diffraction peaks at two-theta positions 4.5°±0.2°, 8.8°±0.2°, and 12.5°±0.2°, and further characterized by X-ray powder diffraction peaks at two-theta positions 10.3°±0.2°, 14.7°±0.2°, 20.6°±0.2°, 22.2°±0.2°, and 26.1°±0.2°;

Form C characterized by X-ray powder diffraction peaks at two-theta positions 11.9°±0.2°, 14.3°±0.2° and 22.3°±0.2°, and further characterized by X-ray powder diffraction peaks at two-theta positions 12.8°±0.2°, 18.5°±0.2°, 21.2°±0.2°, 24.3°±0.2°, and 26.0°±0.2°; and

Form D characterized by X-ray powder diffraction peaks at two-theta positions 6.6°±0.2°, 11.6°±0.2°, and 17.1°±0.2°, and further characterized by X-ray powder diffraction peaks at two-theta positions 15.0°±0.2°, 19.2°±0.2°, 20.5°±0.2°, 21.6°±0.2°, and 29.8°±0.2°.

2. A pharmaceutical composition according to claim 1 , wherein the composition is a solid composition.

3. A pharmaceutical composition according to claim 1 further comprising a wetting agent.

4. A pharmaceutical composition according to claim 3 wherein the wetting agent is Tween.

5. A pharmaceutical composition according claim 1 wherein the composition is in the form of a tablet.

6. A pharmaceutical composition according to claim 5 which is film-coated.

7. A process for preparing a pharmaceutical composition comprising (1) a pharmaceutically acceptable carrier comprising a binder; a wetting agent; a diluent; a disintegrant; optionally a glidant; and optionally a lubricant; and (2) a compound of formula (I-a)

wherein the compound of formula (I-a) is a polymorphic form selected from the group consisting of:

Form B characterized by x-ray powder diffraction peaks at two-theta positions 4.5°±0.2°, 8.8°±0.2°, and 12.5°±0.2°, and further characterized by X-ray powder diffraction peaks at two-theta positions 10.3°±0.2°, 14.7°±0.2°, 20.6°±0.2°, 22.2°±0.2°, and 26.1°±0.2°;

Form C characterized by X-ray powder diffraction peaks at two-theta positions 11.9°±0.2°, 14.3°±0.2° and 22.3°±0.2°, and further characterized by X-ray powder diffraction peaks at two-theta positions 12.8°±0.2°, 18.5°±0.2°, 21.2°±0.2°, 24.3°±0.2°, and 26.0°±0.2°;

Form D characterized by X-ray powder diffraction peaks at two-theta positions 6.6°±0.2°, 11.6°±0.2°, and 17.1°±0.2°, and further characterized by X-ray powder diffraction peaks at two-theta positions 15.0°±0.2°, 19.2°±0.2°, 20.5°±0.2°, 21.6°±0.2°, and 29.8°±0.2°;

said process comprising the following steps:

(i) dry blending the compound of formula I(a) and part of the diluent;

(ii) preparing a binder solution by dissolving the binder and the wetting agent in the binder solution;

(iii) spraying the binder solution obtained in step (ii) on the mixture obtained in step (i) to form a wet powder;

(iv) drying the wet powder obtained in step (iii) followed by sieving and optionally mixing;

(v) mixing the remaining part of the diluent, the disintegrant and the optional glidant in the mixture obtained in step (iv);

(vi) optionally adding the lubricant to the mixture obtained in step (v);

(vii) compressing the mixture obtained in step (vi) into a tablet; and

(viii) optionally film-coating the tablet obtained in step (vii).